11 October 2016
Oncimmune Holdings plc
("Oncimmune" or the "Company")
Appointment of Carsten Schroeder as Non-Executive Director
Oncimmune Holdings plc (AIM: ONC.L), a leading early cancer detection company developing and commercialising its proprietary EarlyCDT® platform technology, announces the appointment of Carsten Schroeder to the Company's Board as Non-Executive Director.
Carsten has over 20 years of senior leadership experience in the medical diagnostics sector. Since 2014 he has been President of the Diagnostic Division at Grifols, S.A. where he is responsible for global commercial operations and overall strategy, including leading its growth and innovation in Transfusion Medicine and Specialty Diagnostics.
Prior to that, and before its acquisition by Grifols, Carsten was President of Novartis Diagnostics. Carsten joined Novartis Diagnostics in 2010 as Vice President of Commercial Operations for the EMEA region where he oversaw expansion into new markets. During his time at Novartis he was a member of the Vaccines & Diagnostic Division Executive Committee and served as Site Head for its Emeryville campus in California. Carsten has also held executive positions with Boston Scientific, Mallinckrodt (now Covidien) and Boehringer Ingelheim.
Mr. Schroeder holds an MBA from the European School of Management in Paris (ESCP) and a Bachelor of Arts in Economics from the University of Cologne in Germany.
Geoffrey Hamilton-Fairley, CEO of Oncimmune, commented: "I am very pleased to announce the appointment of Carsten and welcome him to the Board. His successful track record of launching new products globally will be invaluable to Oncimmune as we continue to expand across the US, Europe and into Asia."
Commenting on his appointment, Carsten Schroeder said: "Oncimmune's EarlyCDT® platform technology, which can detect cancer up to four years earlier than other methods, could transform current methods of cancer detection and save the lives of patients. The opportunity to join the Board of Oncimmune was extremely appealing and I look forward to working with Geoffrey and the team."
The following information is disclosed pursuant to Schedule Two, paragraph (g) of the AIM Rules for Companies:
- Full name and age: Carsten Schroeder, 50
- Current Directorships: Progenika Biopharma s.l., AdvaMedDX, California Life Science Association, National Blood Foundation
- Past Directorships (within the previous 5 years): None
No further information in connection with his appointment is required to be disclosed under Schedule Two, paragraph (g) of the Aim Rules for Companies.
For further information:
Oncimmune Holdings plc
Geoffrey Hamilton-Fairley, Chief Executive Officer
Zeus Capital Limited (Nominated Adviser and Broker)
Phil Walker, Giles Balleny, Dominic Wilson
+44 (0) 203 829 5000
Consilium Strategic Communications
Chris Gardner, Mary-Jane Elliott, Matthew Neal, Lindsey Neville
+44 (0) 20 3709 5708
Oncimmune is a leading early cancer detection company developing and commercialising its proprietary EarlyCDT® platform technology. Oncimmune has pioneered the development of autoantibody tests that can detect cancer up to four years earlier than other methods and can be applied to a very wide range of solid tumour types. The Company's first product, EarlyCDT®-Lung, was launched in 2012, as a CLIA test in the USA and since then over 145,000 commercial tests have been sold. EarlyCDT®-Lung is available through physicians in the US and also privately in the UK and other regions. EarlyCDT®-Lung is being used in the largest ever randomised trial for the early detection of lung cancer using biomarkers, the National Health Service (NHS) Scotland ECLS study of 12,000 high-risk smokers. EarlyCDT® tests for liver and ovarian cancer are in development.
Oncimmune, headquartered in Nottingham, United Kingdom with testing facilities in the US, joined AIM in May 2016 under the ticker ONC.L. For more information visit www.oncimmune.com
This information is provided by RNS